大黄蟅虫丸和自主神经功能对肝纤维化卵圆细胞生成的调控研究
|
摘要
研究目的
在不影响慢性肝纤维化病程自然发展前提下,分别阻断支配大鼠肝脏的交感神经(sympathetic nerve)、迷走神经(vagus nerve)以降低自主神经系统(autonomic nervous system)的活性,观察自主神经系统对肝卵圆细胞(hepaticoval cell,HOC)活化的调控作用。根据HOC活化细胞数同肝纤维化发展程度病理分级的关系,探讨HOC在慢性肝纤维化病程中所起的确切作用,为以HOC为靶细胞的治疗开拓思路。观察大黄蟅虫丸对慢性肝纤维化大鼠模型HOC的活化作用,了解其在治疗肝纤维化中的科学意义,为中医药治疗肝纤维化提供依据。
研究方法
1.动物分组:取雄性Wistar大鼠96只,体重180±20g,每组12只,随机分为8组,分别为:HOC活化抑制组(迷走神经肝支切断),HOC活化增强组(化学性肝交感神经阻断),肝纤维化模型假手术组,肝纤维化模型组,大黄蟅虫丸高剂量组(按成人5倍剂量),大黄蟅虫丸中剂量组(按成人2.5倍剂量),大黄蟅虫丸常规剂量组(按成人等效剂量),空白对照组。各组给予普通饮食,自由饮水。
2.预处理:HOC活化抑制组行迷走神经肝支切断术;HOC活化增强组以6-羟基多巴胺(6-hydroxydopamine,6-OHDA)建立肝脏去交感神经动物模型,具体方法:6-OHDA临用时用灭菌生理盐水配制成100ml/L的溶液。Wistar大鼠10%水合氯醛腹腔注射麻醉,固定于大鼠手术板上,腹部剪毛,局部消毒,于腹部正中纵行切开一长3cm切口,用镊子轻轻夹出小肠,理出空肠段系膜,找到肠系膜血管,用4号半头皮针刺入肠系膜主干静脉中,并同时注入2ml 6-OHDA(含200μg)。用棉签压迫针眼约8～10min,待针孔出血停止,将小肠还纳腹腔,逐层缝合腹壁,常规饲养;肝纤维化模型假手术组则于造模前行腹腔切开,随后手术缝合,术后常规护理。此三组处理均在肝纤维化造模前15天进行以尽量减少对实验结果的影响。
3.肝纤维化模型的制作:除空白对照组外,其余各组以二甲基亚硝胺(N-Nitrosodimethylamine,DMN)10mg·kg~(-1)剂量大鼠腹腔注射,每周连续3天,每日1次,共4周。干预方法:大黄蟅虫丸高、中、常规剂量组在造模第一天开始中药干预。大鼠每日灌胃剂量:大黄蟅虫丸高、中、常规剂量组分别含生药3.0g/kg、1.5g/kg、0.6g/kg;其余各组以等量生理盐水灌胃作为对照。
4.血清检测:于造模开始后第29日,大鼠以10%水合氯醛(3ml/kg)ip麻醉后,仰卧位固定,打开腹腔,腹主动脉采血,离心获取血清。用放射免疫RIA法检测血清透明质酸(hyaluronic acid,HA)、Ⅲ型前胶原(typeⅢprocollagen,PCⅢ)、层粘连蛋白(Laminin,LN)血清浓度变化。
5.肝组织的采集与处理:腹主动脉采血后,脱颈椎处死大鼠。取0.3～0.4cm厚肝组织,40g/L中性甲醛液固定,24h后逐级酒精脱水,二甲苯透明,56℃石蜡包埋,6μm厚切片,用于免疫组化染色。取1.0cm×0.8cm×0.3cm大小肝组织,40g/L中性甲醛液固定,24h后逐级酒精脱水,二甲苯透明,56℃石蜡包埋,4μm厚切片,用于Mallory染色。取50～100mg肝组织放入Trizol中,置入超低温冰箱保存,用于实时荧光定量PCR检测。
6.肝纤维化程度鉴定:应用Mallory三步染色法判断各组胶原纤维增生程度。判定标准:0期,正常肝脏,无明显胶原纤维增生;Ⅰ期,胶原纤维增生,中央静脉和门脉区有少量星状胶原纤维束放散,但无间隔形成;Ⅱ期,胶原纤维增生,中央静脉和门脉区结缔组织变厚,由此向四周伸出纤维索,形成不完全间隔;Ⅲ期,胶原纤维大量增生,有个别菲薄的完全间隔形成,或较厚的不完全间隔即将形成假小叶;Ⅳ期,形成的完全间隔较厚,假小叶大量形成。
7.卵圆细胞的鉴定与计数:采用免疫组织化学染色,以OV-6作为HOC标志物。免疫组织化学样本制备采用两步法:大鼠肝组织切片脱蜡至水,PBS冲洗、浸泡5分钟,高压热抗原修复,3%H_2O_2室温室温孵育5～10分钟,加抗大鼠OV-6抗体(1:100稀释)孵育,置入湿盒中,4℃过夜;PBS冲洗,滴加二抗;PBS冲洗,加二氨基联苯胺(diaminobenzidine,DAB)显色5～30分钟。苏木精液复染细胞核1分钟;自来水冲洗,盐酸酒精分色1～2次;自来水泡洗5分钟;切片脱水、透明;中性树胶封片。PBS替代一抗作为空白对照染色。取肝组织免疫组化切片,光镜下(10×10)观察OV-6阳性染色细胞的分布,每张切片随机选择5个不同视野,在40×10放大倍数下,应用IPP6.0软件对阳性细胞染色面积进行统计,以5个不同视野面积计数的平均值为每张切片的计数值。
8.统计方法:所有数据处理采用SPSS13.0软件完成,数据均以均数±标准差((?)±s)表示。HOC活化抑制组、HOC活化增强组、肝纤维化模型假手术组、肝纤维化模型组、空白对照组间HOC细胞计数的比较,大黄蟅虫丸高、中、常规剂量组、肝纤维化组模型组、空白对照组对HOC活化的影响结果以及各组间血清学指标的比较,以及各组TIMP-1 mRNA、CTGF mRNA、Notch1 mRNA的差异表达均采用单向方差分析,组间比较如方差齐采用LSD法,方差不齐则采用Dunnett's T3法;各组间肝纤维化病理分期的比较采用非参数检验之KruskalWallis检验。HOC增生与肝纤维化的相关分析采用Spearman相关分析法。
结果
一、自主神经系统及大黄蟅虫丸对肝纤维化病理分期的影响:HOC活化增强组(化学性交感神经阻断)纤维化程度较肝纤维化模型假手术组显著降低;HOC活化抑制组(迷走神经肝支切断)则较肝纤维化模型假手术组纤维化程度加重;肝纤维化模型假手术组与肝纤维化模型纤维化程度无差异。大黄蟅虫丸中剂量组纤维化程度明显低于肝纤维化模型组;大黄蟅虫丸高、常规剂量组纤维化程度低于肝纤维化模型组。
二、自主神经系统及大黄蟅虫丸对血清HA的影响:HOC活化抑制组(迷走神经肝支切断)与肝纤维化模型假手术组比较无显著性差异(P=0.142);与肝纤维化模型假手术组相比,HOC活化增强组(化学性交感神经阻断)HA水平显著降低(P=0.000)。与肝纤维化模型组相比,大黄蟅虫丸高剂量(P=0.003)、中剂量(P=0.000)、常规剂量组(P=0.004)均能显著降低HA水平。
三、自主神经系统及大黄蟅虫丸对血清PCⅢ的影响:与肝纤维化模型假手术组相比,HOC活化抑制组(迷走神经肝支切断)PCⅢ水平显著升高(P=0.007),HOC活化增强组显著(P=0.010)降低。与肝纤维化模型组相比,大黄蟅虫丸高剂量(P=0.040)、大黄蟅虫丸中剂量(P=0.003)可显著降低肝纤维化大鼠模型血清PCⅢ水平。
四、自主神经系统及大黄蟅虫丸对血清LN的影响:与肝纤维化模型假手术组相比,HOC活化抑制组(迷走神经肝支切断)无显著性差异(P=0.148);HOC活化增强组(化学性交感神经阻断)LN水平显著降低(P=0.001)。与肝纤维化模型组相比,大黄蟅虫丸中剂量(P=0.001)、常规剂量(P=0.048)可显著降低肝纤维化大鼠模型血清LN水平,大黄蟅虫丸高剂量组(P=0.146)差异无统计学意义。
五、自主神经系统及大黄蟅虫丸对肝纤维化模型大鼠HOC增殖的影响:与肝纤维化模型假手术组相比,HOC活化抑制组(迷走神经肝支切断)、HOC活化增强组(化学性交感神经阻断)均有显著性差异(P=0.000),HOC活化抑制与HOC活化增强分别能抑制、促进HOC的增生。与肝纤维化模型组相比,大黄蟅虫丸高、中、常规剂量组均可显著降低DMN肝纤维化大鼠模型HOC增殖(P<0.05)。
六、HOC活化增殖与肝纤维分级的相关性分析
1.自主神经系统对HOC活化增殖与肝纤维化分级相关性分析将HOC活化抑制组(迷走神经肝支切断)、HOC活化增强组(化学性交感神经阻断)、肝纤维化模型假手术组纳入统计范围。结果显示:r_p＝-0.776,P＝0.000,两者存在显著负相关关系。即随着HOC数量的增多,纤维化程度呈下降趋势。
2.大黄蟅虫丸对HOC活化增殖与肝纤维化分级相关性分析将大黄蟅虫丸高、中、常规剂量组、肝纤维化模型组纳入统计范围。结果显示:r_p＝0.602,P＝0.002,两者存在显著正相关关系。即HOC活化数量越少,肝纤维化程度越低。
七、自主神经系统及大黄蟅虫丸对肝纤维化模型大鼠TIMP-1 mRNA、CTGFmRNA、Notch1 mRNA表达的影响:与肝纤维化模型假手术组相比,HOC活化抑制组(迷走神经肝支切断)、HOC活化增强组(化学性交感神经阻断)TIMP-1m RNA、CTGF mRNA、Notch1 mRNA的表达均显著下调。与肝纤维化模型组相比,大黄蟅虫丸各剂量组TIMP-1m RNA、CTGF mRNA、Notch1 mRNA的表达均显著下调(P＜0.01)。
结论
一、交感神经系统(sympathetic nervous system,SNS)抑制剂(SNSIs)可以显著降低DMN肝纤维化大鼠纤维化程度,保护实验动物肝损伤;迷走神经阻断则加重DMN大鼠纤维化、损伤程度。
二、SNSIs通过SNS对肝星状细胞(hepatic stellate cell,HSC)和HOC的直接调节影响对损伤肝脏的修复;推测大鼠的肝脏祖细胞可能表达M3型受体,迷走神经肝支通过乙酰胆碱(ACh)结合M3型受体刺激了卵圆细胞的激活。
三、大黄蟅虫丸抗纤维化机制之一是抑制了TIMP-1的活性,降低了与MMPs的结合,使MMPs对ECM的降解作用增强;大黄蟅虫丸可以抑制HSC的增殖,促进MMPs对ECM的降解,体现了其“化瘀”的作用。
四、大黄蟅虫丸抗纤维化的机制与下调纤维化病程中过度表达的CTGFmRNA有关。CTGF被抑制,其促ECM合成的作用减弱,有利于ECM降解,是“化瘀”的另一种体现;其表达细胞黏附因子的作用减弱,使细胞不易黏附和结合基质蛋白,脱离纤维趋化环境,此即中医“活血”思想的体现。
五、大黄蟅虫丸通过下调Notch1 mRNA的表达诱导HOC向肝细胞方向分化。
六、在慢性肝维化病理状态下,HOC的激活是一种机体自身适应性反应,便于肝脏的修复;但长期地处于这种状态,HOC的过度活跃、增生导致肝脏结构、功能破坏和肝癌的发生。
Objective
The activity of sympathetic nervous system(SNS) and parasympathetic nervous system(PNS) was separately inhibited in order to regulate the accumulation of HOC (hepatic oval cell) in liver fibrosis。Then.the relationship between the degree of activated HOCs and the liver fibrosis was evaluated to determine whether the HOC effects chronic liver fibrosis.HOC activation may be a useful therapeutic approach to cure liver fibrosis.To investigate how the dahuangzhechongwan affect the regulation of HOC in liver fibrosis.
Methods
1.Animals:96 male Wistar rats,180±20g,were randomly divided into 8 groups, each group contains 12 rats.respectively:the group of inhibited HOC activation (hepatic branch of vagus nerve cut),the group of enhanced HOC activation(chemical hepatic sympathetic inhibition),the group of liver fibrosis model with sham operation, the group of liver fibrosis model,the group of dahuangzhechongwan with conventional dose(according to the adult dose),the group of dahuangzhechongwan with middle dose(2.5 times of the adult dose),the group of dahuangzhechongwan with high dose(5 times of the adult dose),control group.Each group was given ordinary feed,free from drinking water.
2.Pretreatment:The group of inhibited HOC activation was cut the vagus nerve of liver branch with surgery;The group of enhanced HOC activation was given the 6-hydroxydopamine(6-OHDA) to set up chemical sympathectomy animal model,. Methods:6-OHDA was configured to 100mg/L solution with sterile saline before operation.Rats were anesthetized with 10%chloral hydrate anesthesia,then fixed on the surgery board.After shearing and disinfection,we make a long longitudinal incision about 3cm in the middle of abdomen,then pull out the intestine gently with tweezers.The mesenteric blood vessel was found out in jejunal segment mesenteric. Then the superior mesenteric vein was pierced with scalp acupuncture,at the same time,2ml 6-OHDA(containing 200μg) was injected into the vein.After oppressing on the eye of a needle with cotton for about 8～10min,the abdominal wall was sutured the layer-by-layer.Then these rats was bred conventional;Rats of liver fibrosis model with sham operation were treated by abdominal incision and exploratory laparotomy,followed by surgical suture,then was bred conventionally. These three group model was made 15 days before liver fibrosis model in order to minimize the impact on the experimental results.
3.Liver fibrosis model:In addition to the control group,the other groups,were injected with DMN(dimethylnitrosamine) of 10mg.kg~(-1) intraperitoneal according to the Matsuda's method.Interventions:Dahuangzhechongwan conventional dose, middle dose and high dose group were intervened on the first day of making liver fibrosis model with the dose of 0.6g/kg,1.5g/kg,3.0g/kg corresponding.The other groups were bred conventionally.
4.Serum testing:29 days after injection,all rats were anesthetized with 10% chloral hydrate anesthesia,fixed with the supine position,cut the abdominal cavity. Blood was collected from abdominal aorta,serum was collected through centrifugation.The difference in hyaluronic acid(hyaluronic acid,HA),Ⅲprocollagen type(typeⅢprocollagen,PCⅢ),laminin(Laminin,LN) was tested through radioimmunoassay RIA.
5.Treatment of liver tissue:After the collection of blood,all rats were killed from cervical dislocation.A liver tissue about 0.3～0.4cm was choosed and fixed by formaldehyde solution of 40g/L.dehydrated through each grade of alcohol after 24h, dealed with dimethylbenzene,paraffin-embedded in 56℃.made a slice of 6μm thick for immunohistochemical staining.Liver tissue of 1.0cm×0.8cm×0.3cm was choosed and fixed by neutral formaldehyde solution of 40g/L,dehydrated through each level of alcohol after 24 h,dealed with dimethylbenzene,embedded in 56℃by paraffin, made a slice of 4μm for Mallory staining.Liver tissue of 50～100mg was mixed with Trizol in order to real time PCR.
6.The stage of hepatic fibrosis:A three-step method of collagen fibers staining, Mallory was used to identified the degree of proliferation in each group.Criteria:0 period,normal liver,no significant proliferation of collagen fibers;Ⅰperiod, proliferation of collagen fibers is founded,there is a small amount of stellate collagen fibers in the central vein and portal area,but there is no fibrous septa;Ⅱperiod, proliferation of collagen fibers is founded,connective tissues in portal vein and central vein become thickening,which reach out fiber cables all-around,and become incomplete fibrous septa;Ⅲperiod,substantial proliferation of collagen fibers is founded,some of which forms thin complete fibrous septa,or some thick incomplete fibrous septa is about to forming pseudo lobule;Ⅳperiod,the complete fibrous septa is rather thick,a lot of pseudo lobules were found.
7.Identification of the HOC:OV-6 was used to mark the HOC during the period of immunohistochemistry.A two-step sample preparation was used for immunohisto-chemistry: Liver tissue slices were fixed with acetone for 10mins,then dealed with H_2O_2 of 3ml/L at room temperature for 30min.The slices were incubated with Anti-rat OV-6 antibody(diluted by 1:100) in wet box,overnight at 4℃temperature; The slices were incubated with horseradish peroxidase(HRP) in wet box for 30mins at 37℃temperature.Then diaminobenzidine(DAB) was added onto it for 3～5mins. The nuclei were stained by hematoxylin for 10s.Sections were sealed by balsam neutral.Instead of first antibody,PBS was used to stain as blank control.We observe the rat liver tissue sections to distribution the cells with OV-6 immunohistochemical staining through light microscopy(10×10).After five different fields of vision randomly selected we count the cells of positive staining at 40×10 magnification.The average of cell numbers in five different fields is the cell numbers of each section. 8.The statistics method:All data was processed by spss13.0,and was expressed as mean number±standard deviation((?)±s ).One Way ANOVA was used to analysis the difference between groups such as the activation of HOC.TIMP-1 mRNA,CTGF mRNA or Notch1 mRNA;Kruskal Wallis was used to analysis the difference of the stage of liver fibrosis.Spearman was used to analysis the relationship between the regulation of HOC and the stage of liver fibrosis.
Results
1.The statistics shows significant differences between all groups.Compared with group of liver fibrosis model with sham operation,either group of inhibited HOC activation or group of enhanced HOC activation has quite different degree of liver fibrosis.The group of inhibited HOC activation is more serious than the group of liver fibrosis model with sham operation,the group of enhanced HOC activation is less serious than it.The statistics shows no significant differences between the group of liver fibrosis model with sham operation and the group of liver fibrosis model. Compared with the group of liver fibrosis model,the groups of dahuangzhechongwan with different dose is less serious on the degree of liver fibrosis.
2.Comparison of HA:In contrast with group of liver fibrosis model with sham operation,the group of enhanced HOC activation has quite different HA.Compared with group of liver fibrosis model,the group of dahuangzhechongwan with three different dose can reduce the degree of HA.
3.Comparison of PCⅢ:In contrast with group of liver fibrosis model with sham operation,either group of inhibited HOC activation or group of enhanced HOC activation has quite different PCⅢ.The statistics shows significant differences between these three groups.Compared with the group of liver fibrosis model,either group of dahuangzhechongwan with middle dose or group of dahuangzhechongwan with high dose has quite different PCⅢ.
4.Comparison of LN:Compared with the group of liver fibrosis model with sham operation,the group of enhanced HOC activation has less LN.The statistics shows significant differences between these two groups.In contrast with group of liver fibrosis model,either group of dahuangzhechongwan with middle dose or group of dahuangzhechongwan with conventional dose has quite different LN.
5.Comparison of activated HOCs:In contrast with group of liver fibrosis model with sham operation,either group of inhibited HOC activation or group of enhanced HOC activation has quite different activated HOCs.The statistics shows significant differences between these three groups.The group of dahuangzhechongwan with middle dose has less activated HOCs than that of the group of liver fibrosis model.
6.Spearman correlation analysis between HOC activation and liver fibrosis period:
Overall correlation analysis taking into account with all groups except control group shows there is no correlation between HOC activation and liver fibrosis period, whose rp is -0.117 and the P is 0.459.
Correlation analysis in the effects of sympathetic nervous system and parasympathetic nervous system(taking into account of group of inhibited HOC activation,group of enhanced HOC activation and group of liver fibrosis model with sham operation) shows there is obvious negative correlation between activated HOCs and liver fibrosis period,which is more activated HOCs,less liver fibrosis(rp＝-0.776, P＝0.000).
Correlation analysis in the effects of dahuangzhechongwan with different doses (taking into account three groups of dahuangzhechongwan with different doses and group of liver fibrosis model) show there is obvious positive correlation between activated HOCs and liver fibrosis period,which is less activated HOCs,less liver fibrosis(rp＝0.602,P＝0.002).
7.In contrast with group of liver fibrosis model with sham operation,either group of inhibited HOC activation or group of enhanced HOC activation has quite different TIMP-1 mRNA,CTGF mRNA,Notch1 mRNA.Compared with the group of liver fibrosis model,the group of enhanced HOC activation has quite different TIMP-1 mRNA,CTGF mRNA,Notch1 mRNA.
Conclusion
1.SNSIs can protect experimental animals from liver fibrosis.Inhibiting the hepatic branch of vagus nerve can increase the degree of fibrosis.
2.SNS has direct impect on HSC and HOC,which will influence the liver repairement.Receptor Type M3 can also be expressed by HPC of rats.Vagus nerve affect the proliferation of HOC through M3 Recepter of Ach.
3.Dahuangzhechongwan can inhibit the energy of TIMP-1 and reducing the combination with MMPs resulted in strenthing MMPs'S degration to ECM.The growth of HSC can be inhibited by dahuangzhechongwan.In that case,it can not only reduce the origin of TIMP-1 but also accelerate MMPs's degration to ECM.
4.Dahuangzhechongwan is related to CTGF mRNA which was over expressed though the process of adjustment the combination of ECM can be weakened through being inhibited CTGF,but it was good to degration which is another reflection of promoting blood circulation.
5.Dahuangzhechongwan can induce HOC to diversify into liver cell through down-regulating the expression of Notch1 mRNA.
6.The activation of HOC maybe an organic responsive reaction under the chronic liver fibrosis.Excessive activation of HOC may lead to cancer.
在不影响慢性肝纤维化病程自然发展前提下,分别阻断支配大鼠肝脏的交感神经(sympathetic nerve)、迷走神经(vagus nerve)以降低自主神经系统(autonomic nervous system)的活性,观察自主神经系统对肝卵圆细胞(hepaticoval cell,HOC)活化的调控作用。根据HOC活化细胞数同肝纤维化发展程度病理分级的关系,探讨HOC在慢性肝纤维化病程中所起的确切作用,为以HOC为靶细胞的治疗开拓思路。观察大黄蟅虫丸对慢性肝纤维化大鼠模型HOC的活化作用,了解其在治疗肝纤维化中的科学意义,为中医药治疗肝纤维化提供依据。
研究方法
1.动物分组:取雄性Wistar大鼠96只,体重180±20g,每组12只,随机分为8组,分别为:HOC活化抑制组(迷走神经肝支切断),HOC活化增强组(化学性肝交感神经阻断),肝纤维化模型假手术组,肝纤维化模型组,大黄蟅虫丸高剂量组(按成人5倍剂量),大黄蟅虫丸中剂量组(按成人2.5倍剂量),大黄蟅虫丸常规剂量组(按成人等效剂量),空白对照组。各组给予普通饮食,自由饮水。
2.预处理:HOC活化抑制组行迷走神经肝支切断术;HOC活化增强组以6-羟基多巴胺(6-hydroxydopamine,6-OHDA)建立肝脏去交感神经动物模型,具体方法:6-OHDA临用时用灭菌生理盐水配制成100ml/L的溶液。Wistar大鼠10%水合氯醛腹腔注射麻醉,固定于大鼠手术板上,腹部剪毛,局部消毒,于腹部正中纵行切开一长3cm切口,用镊子轻轻夹出小肠,理出空肠段系膜,找到肠系膜血管,用4号半头皮针刺入肠系膜主干静脉中,并同时注入2ml 6-OHDA(含200μg)。用棉签压迫针眼约8～10min,待针孔出血停止,将小肠还纳腹腔,逐层缝合腹壁,常规饲养;肝纤维化模型假手术组则于造模前行腹腔切开,随后手术缝合,术后常规护理。此三组处理均在肝纤维化造模前15天进行以尽量减少对实验结果的影响。
3.肝纤维化模型的制作:除空白对照组外,其余各组以二甲基亚硝胺(N-Nitrosodimethylamine,DMN)10mg·kg~(-1)剂量大鼠腹腔注射,每周连续3天,每日1次,共4周。干预方法:大黄蟅虫丸高、中、常规剂量组在造模第一天开始中药干预。大鼠每日灌胃剂量:大黄蟅虫丸高、中、常规剂量组分别含生药3.0g/kg、1.5g/kg、0.6g/kg;其余各组以等量生理盐水灌胃作为对照。
4.血清检测:于造模开始后第29日,大鼠以10%水合氯醛(3ml/kg)ip麻醉后,仰卧位固定,打开腹腔,腹主动脉采血,离心获取血清。用放射免疫RIA法检测血清透明质酸(hyaluronic acid,HA)、Ⅲ型前胶原(typeⅢprocollagen,PCⅢ)、层粘连蛋白(Laminin,LN)血清浓度变化。
5.肝组织的采集与处理:腹主动脉采血后,脱颈椎处死大鼠。取0.3～0.4cm厚肝组织,40g/L中性甲醛液固定,24h后逐级酒精脱水,二甲苯透明,56℃石蜡包埋,6μm厚切片,用于免疫组化染色。取1.0cm×0.8cm×0.3cm大小肝组织,40g/L中性甲醛液固定,24h后逐级酒精脱水,二甲苯透明,56℃石蜡包埋,4μm厚切片,用于Mallory染色。取50～100mg肝组织放入Trizol中,置入超低温冰箱保存,用于实时荧光定量PCR检测。
6.肝纤维化程度鉴定:应用Mallory三步染色法判断各组胶原纤维增生程度。判定标准:0期,正常肝脏,无明显胶原纤维增生;Ⅰ期,胶原纤维增生,中央静脉和门脉区有少量星状胶原纤维束放散,但无间隔形成;Ⅱ期,胶原纤维增生,中央静脉和门脉区结缔组织变厚,由此向四周伸出纤维索,形成不完全间隔;Ⅲ期,胶原纤维大量增生,有个别菲薄的完全间隔形成,或较厚的不完全间隔即将形成假小叶;Ⅳ期,形成的完全间隔较厚,假小叶大量形成。
7.卵圆细胞的鉴定与计数:采用免疫组织化学染色,以OV-6作为HOC标志物。免疫组织化学样本制备采用两步法:大鼠肝组织切片脱蜡至水,PBS冲洗、浸泡5分钟,高压热抗原修复,3%H_2O_2室温室温孵育5～10分钟,加抗大鼠OV-6抗体(1:100稀释)孵育,置入湿盒中,4℃过夜;PBS冲洗,滴加二抗;PBS冲洗,加二氨基联苯胺(diaminobenzidine,DAB)显色5～30分钟。苏木精液复染细胞核1分钟;自来水冲洗,盐酸酒精分色1～2次;自来水泡洗5分钟;切片脱水、透明;中性树胶封片。PBS替代一抗作为空白对照染色。取肝组织免疫组化切片,光镜下(10×10)观察OV-6阳性染色细胞的分布,每张切片随机选择5个不同视野,在40×10放大倍数下,应用IPP6.0软件对阳性细胞染色面积进行统计,以5个不同视野面积计数的平均值为每张切片的计数值。
8.统计方法:所有数据处理采用SPSS13.0软件完成,数据均以均数±标准差((?)±s)表示。HOC活化抑制组、HOC活化增强组、肝纤维化模型假手术组、肝纤维化模型组、空白对照组间HOC细胞计数的比较,大黄蟅虫丸高、中、常规剂量组、肝纤维化组模型组、空白对照组对HOC活化的影响结果以及各组间血清学指标的比较,以及各组TIMP-1 mRNA、CTGF mRNA、Notch1 mRNA的差异表达均采用单向方差分析,组间比较如方差齐采用LSD法,方差不齐则采用Dunnett's T3法;各组间肝纤维化病理分期的比较采用非参数检验之KruskalWallis检验。HOC增生与肝纤维化的相关分析采用Spearman相关分析法。
结果
一、自主神经系统及大黄蟅虫丸对肝纤维化病理分期的影响:HOC活化增强组(化学性交感神经阻断)纤维化程度较肝纤维化模型假手术组显著降低;HOC活化抑制组(迷走神经肝支切断)则较肝纤维化模型假手术组纤维化程度加重;肝纤维化模型假手术组与肝纤维化模型纤维化程度无差异。大黄蟅虫丸中剂量组纤维化程度明显低于肝纤维化模型组;大黄蟅虫丸高、常规剂量组纤维化程度低于肝纤维化模型组。
二、自主神经系统及大黄蟅虫丸对血清HA的影响:HOC活化抑制组(迷走神经肝支切断)与肝纤维化模型假手术组比较无显著性差异(P=0.142);与肝纤维化模型假手术组相比,HOC活化增强组(化学性交感神经阻断)HA水平显著降低(P=0.000)。与肝纤维化模型组相比,大黄蟅虫丸高剂量(P=0.003)、中剂量(P=0.000)、常规剂量组(P=0.004)均能显著降低HA水平。
三、自主神经系统及大黄蟅虫丸对血清PCⅢ的影响:与肝纤维化模型假手术组相比,HOC活化抑制组(迷走神经肝支切断)PCⅢ水平显著升高(P=0.007),HOC活化增强组显著(P=0.010)降低。与肝纤维化模型组相比,大黄蟅虫丸高剂量(P=0.040)、大黄蟅虫丸中剂量(P=0.003)可显著降低肝纤维化大鼠模型血清PCⅢ水平。
四、自主神经系统及大黄蟅虫丸对血清LN的影响:与肝纤维化模型假手术组相比,HOC活化抑制组(迷走神经肝支切断)无显著性差异(P=0.148);HOC活化增强组(化学性交感神经阻断)LN水平显著降低(P=0.001)。与肝纤维化模型组相比,大黄蟅虫丸中剂量(P=0.001)、常规剂量(P=0.048)可显著降低肝纤维化大鼠模型血清LN水平,大黄蟅虫丸高剂量组(P=0.146)差异无统计学意义。
五、自主神经系统及大黄蟅虫丸对肝纤维化模型大鼠HOC增殖的影响:与肝纤维化模型假手术组相比,HOC活化抑制组(迷走神经肝支切断)、HOC活化增强组(化学性交感神经阻断)均有显著性差异(P=0.000),HOC活化抑制与HOC活化增强分别能抑制、促进HOC的增生。与肝纤维化模型组相比,大黄蟅虫丸高、中、常规剂量组均可显著降低DMN肝纤维化大鼠模型HOC增殖(P<0.05)。
六、HOC活化增殖与肝纤维分级的相关性分析
1.自主神经系统对HOC活化增殖与肝纤维化分级相关性分析将HOC活化抑制组(迷走神经肝支切断)、HOC活化增强组(化学性交感神经阻断)、肝纤维化模型假手术组纳入统计范围。结果显示:r_p＝-0.776,P＝0.000,两者存在显著负相关关系。即随着HOC数量的增多,纤维化程度呈下降趋势。
2.大黄蟅虫丸对HOC活化增殖与肝纤维化分级相关性分析将大黄蟅虫丸高、中、常规剂量组、肝纤维化模型组纳入统计范围。结果显示:r_p＝0.602,P＝0.002,两者存在显著正相关关系。即HOC活化数量越少,肝纤维化程度越低。
七、自主神经系统及大黄蟅虫丸对肝纤维化模型大鼠TIMP-1 mRNA、CTGFmRNA、Notch1 mRNA表达的影响:与肝纤维化模型假手术组相比,HOC活化抑制组(迷走神经肝支切断)、HOC活化增强组(化学性交感神经阻断)TIMP-1m RNA、CTGF mRNA、Notch1 mRNA的表达均显著下调。与肝纤维化模型组相比,大黄蟅虫丸各剂量组TIMP-1m RNA、CTGF mRNA、Notch1 mRNA的表达均显著下调(P＜0.01)。
结论
一、交感神经系统(sympathetic nervous system,SNS)抑制剂(SNSIs)可以显著降低DMN肝纤维化大鼠纤维化程度,保护实验动物肝损伤;迷走神经阻断则加重DMN大鼠纤维化、损伤程度。
二、SNSIs通过SNS对肝星状细胞(hepatic stellate cell,HSC)和HOC的直接调节影响对损伤肝脏的修复;推测大鼠的肝脏祖细胞可能表达M3型受体,迷走神经肝支通过乙酰胆碱(ACh)结合M3型受体刺激了卵圆细胞的激活。
三、大黄蟅虫丸抗纤维化机制之一是抑制了TIMP-1的活性,降低了与MMPs的结合,使MMPs对ECM的降解作用增强;大黄蟅虫丸可以抑制HSC的增殖,促进MMPs对ECM的降解,体现了其“化瘀”的作用。
四、大黄蟅虫丸抗纤维化的机制与下调纤维化病程中过度表达的CTGFmRNA有关。CTGF被抑制,其促ECM合成的作用减弱,有利于ECM降解,是“化瘀”的另一种体现;其表达细胞黏附因子的作用减弱,使细胞不易黏附和结合基质蛋白,脱离纤维趋化环境,此即中医“活血”思想的体现。
五、大黄蟅虫丸通过下调Notch1 mRNA的表达诱导HOC向肝细胞方向分化。
六、在慢性肝维化病理状态下,HOC的激活是一种机体自身适应性反应,便于肝脏的修复;但长期地处于这种状态,HOC的过度活跃、增生导致肝脏结构、功能破坏和肝癌的发生。
Objective
The activity of sympathetic nervous system(SNS) and parasympathetic nervous system(PNS) was separately inhibited in order to regulate the accumulation of HOC (hepatic oval cell) in liver fibrosis。Then.the relationship between the degree of activated HOCs and the liver fibrosis was evaluated to determine whether the HOC effects chronic liver fibrosis.HOC activation may be a useful therapeutic approach to cure liver fibrosis.To investigate how the dahuangzhechongwan affect the regulation of HOC in liver fibrosis.
Methods
1.Animals:96 male Wistar rats,180±20g,were randomly divided into 8 groups, each group contains 12 rats.respectively:the group of inhibited HOC activation (hepatic branch of vagus nerve cut),the group of enhanced HOC activation(chemical hepatic sympathetic inhibition),the group of liver fibrosis model with sham operation, the group of liver fibrosis model,the group of dahuangzhechongwan with conventional dose(according to the adult dose),the group of dahuangzhechongwan with middle dose(2.5 times of the adult dose),the group of dahuangzhechongwan with high dose(5 times of the adult dose),control group.Each group was given ordinary feed,free from drinking water.
2.Pretreatment:The group of inhibited HOC activation was cut the vagus nerve of liver branch with surgery;The group of enhanced HOC activation was given the 6-hydroxydopamine(6-OHDA) to set up chemical sympathectomy animal model,. Methods:6-OHDA was configured to 100mg/L solution with sterile saline before operation.Rats were anesthetized with 10%chloral hydrate anesthesia,then fixed on the surgery board.After shearing and disinfection,we make a long longitudinal incision about 3cm in the middle of abdomen,then pull out the intestine gently with tweezers.The mesenteric blood vessel was found out in jejunal segment mesenteric. Then the superior mesenteric vein was pierced with scalp acupuncture,at the same time,2ml 6-OHDA(containing 200μg) was injected into the vein.After oppressing on the eye of a needle with cotton for about 8～10min,the abdominal wall was sutured the layer-by-layer.Then these rats was bred conventional;Rats of liver fibrosis model with sham operation were treated by abdominal incision and exploratory laparotomy,followed by surgical suture,then was bred conventionally. These three group model was made 15 days before liver fibrosis model in order to minimize the impact on the experimental results.
3.Liver fibrosis model:In addition to the control group,the other groups,were injected with DMN(dimethylnitrosamine) of 10mg.kg~(-1) intraperitoneal according to the Matsuda's method.Interventions:Dahuangzhechongwan conventional dose, middle dose and high dose group were intervened on the first day of making liver fibrosis model with the dose of 0.6g/kg,1.5g/kg,3.0g/kg corresponding.The other groups were bred conventionally.
4.Serum testing:29 days after injection,all rats were anesthetized with 10% chloral hydrate anesthesia,fixed with the supine position,cut the abdominal cavity. Blood was collected from abdominal aorta,serum was collected through centrifugation.The difference in hyaluronic acid(hyaluronic acid,HA),Ⅲprocollagen type(typeⅢprocollagen,PCⅢ),laminin(Laminin,LN) was tested through radioimmunoassay RIA.
5.Treatment of liver tissue:After the collection of blood,all rats were killed from cervical dislocation.A liver tissue about 0.3～0.4cm was choosed and fixed by formaldehyde solution of 40g/L.dehydrated through each grade of alcohol after 24h, dealed with dimethylbenzene,paraffin-embedded in 56℃.made a slice of 6μm thick for immunohistochemical staining.Liver tissue of 1.0cm×0.8cm×0.3cm was choosed and fixed by neutral formaldehyde solution of 40g/L,dehydrated through each level of alcohol after 24 h,dealed with dimethylbenzene,embedded in 56℃by paraffin, made a slice of 4μm for Mallory staining.Liver tissue of 50～100mg was mixed with Trizol in order to real time PCR.
6.The stage of hepatic fibrosis:A three-step method of collagen fibers staining, Mallory was used to identified the degree of proliferation in each group.Criteria:0 period,normal liver,no significant proliferation of collagen fibers;Ⅰperiod, proliferation of collagen fibers is founded,there is a small amount of stellate collagen fibers in the central vein and portal area,but there is no fibrous septa;Ⅱperiod, proliferation of collagen fibers is founded,connective tissues in portal vein and central vein become thickening,which reach out fiber cables all-around,and become incomplete fibrous septa;Ⅲperiod,substantial proliferation of collagen fibers is founded,some of which forms thin complete fibrous septa,or some thick incomplete fibrous septa is about to forming pseudo lobule;Ⅳperiod,the complete fibrous septa is rather thick,a lot of pseudo lobules were found.
7.Identification of the HOC:OV-6 was used to mark the HOC during the period of immunohistochemistry.A two-step sample preparation was used for immunohisto-chemistry: Liver tissue slices were fixed with acetone for 10mins,then dealed with H_2O_2 of 3ml/L at room temperature for 30min.The slices were incubated with Anti-rat OV-6 antibody(diluted by 1:100) in wet box,overnight at 4℃temperature; The slices were incubated with horseradish peroxidase(HRP) in wet box for 30mins at 37℃temperature.Then diaminobenzidine(DAB) was added onto it for 3～5mins. The nuclei were stained by hematoxylin for 10s.Sections were sealed by balsam neutral.Instead of first antibody,PBS was used to stain as blank control.We observe the rat liver tissue sections to distribution the cells with OV-6 immunohistochemical staining through light microscopy(10×10).After five different fields of vision randomly selected we count the cells of positive staining at 40×10 magnification.The average of cell numbers in five different fields is the cell numbers of each section. 8.The statistics method:All data was processed by spss13.0,and was expressed as mean number±standard deviation((?)±s ).One Way ANOVA was used to analysis the difference between groups such as the activation of HOC.TIMP-1 mRNA,CTGF mRNA or Notch1 mRNA;Kruskal Wallis was used to analysis the difference of the stage of liver fibrosis.Spearman was used to analysis the relationship between the regulation of HOC and the stage of liver fibrosis.
Results
1.The statistics shows significant differences between all groups.Compared with group of liver fibrosis model with sham operation,either group of inhibited HOC activation or group of enhanced HOC activation has quite different degree of liver fibrosis.The group of inhibited HOC activation is more serious than the group of liver fibrosis model with sham operation,the group of enhanced HOC activation is less serious than it.The statistics shows no significant differences between the group of liver fibrosis model with sham operation and the group of liver fibrosis model. Compared with the group of liver fibrosis model,the groups of dahuangzhechongwan with different dose is less serious on the degree of liver fibrosis.
2.Comparison of HA:In contrast with group of liver fibrosis model with sham operation,the group of enhanced HOC activation has quite different HA.Compared with group of liver fibrosis model,the group of dahuangzhechongwan with three different dose can reduce the degree of HA.
3.Comparison of PCⅢ:In contrast with group of liver fibrosis model with sham operation,either group of inhibited HOC activation or group of enhanced HOC activation has quite different PCⅢ.The statistics shows significant differences between these three groups.Compared with the group of liver fibrosis model,either group of dahuangzhechongwan with middle dose or group of dahuangzhechongwan with high dose has quite different PCⅢ.
4.Comparison of LN:Compared with the group of liver fibrosis model with sham operation,the group of enhanced HOC activation has less LN.The statistics shows significant differences between these two groups.In contrast with group of liver fibrosis model,either group of dahuangzhechongwan with middle dose or group of dahuangzhechongwan with conventional dose has quite different LN.
5.Comparison of activated HOCs:In contrast with group of liver fibrosis model with sham operation,either group of inhibited HOC activation or group of enhanced HOC activation has quite different activated HOCs.The statistics shows significant differences between these three groups.The group of dahuangzhechongwan with middle dose has less activated HOCs than that of the group of liver fibrosis model.
6.Spearman correlation analysis between HOC activation and liver fibrosis period:
Overall correlation analysis taking into account with all groups except control group shows there is no correlation between HOC activation and liver fibrosis period, whose rp is -0.117 and the P is 0.459.
Correlation analysis in the effects of sympathetic nervous system and parasympathetic nervous system(taking into account of group of inhibited HOC activation,group of enhanced HOC activation and group of liver fibrosis model with sham operation) shows there is obvious negative correlation between activated HOCs and liver fibrosis period,which is more activated HOCs,less liver fibrosis(rp＝-0.776, P＝0.000).
Correlation analysis in the effects of dahuangzhechongwan with different doses (taking into account three groups of dahuangzhechongwan with different doses and group of liver fibrosis model) show there is obvious positive correlation between activated HOCs and liver fibrosis period,which is less activated HOCs,less liver fibrosis(rp＝0.602,P＝0.002).
7.In contrast with group of liver fibrosis model with sham operation,either group of inhibited HOC activation or group of enhanced HOC activation has quite different TIMP-1 mRNA,CTGF mRNA,Notch1 mRNA.Compared with the group of liver fibrosis model,the group of enhanced HOC activation has quite different TIMP-1 mRNA,CTGF mRNA,Notch1 mRNA.
Conclusion
1.SNSIs can protect experimental animals from liver fibrosis.Inhibiting the hepatic branch of vagus nerve can increase the degree of fibrosis.
2.SNS has direct impect on HSC and HOC,which will influence the liver repairement.Receptor Type M3 can also be expressed by HPC of rats.Vagus nerve affect the proliferation of HOC through M3 Recepter of Ach.
3.Dahuangzhechongwan can inhibit the energy of TIMP-1 and reducing the combination with MMPs resulted in strenthing MMPs'S degration to ECM.The growth of HSC can be inhibited by dahuangzhechongwan.In that case,it can not only reduce the origin of TIMP-1 but also accelerate MMPs's degration to ECM.
4.Dahuangzhechongwan is related to CTGF mRNA which was over expressed though the process of adjustment the combination of ECM can be weakened through being inhibited CTGF,but it was good to degration which is another reflection of promoting blood circulation.
5.Dahuangzhechongwan can induce HOC to diversify into liver cell through down-regulating the expression of Notch1 mRNA.
6.The activation of HOC maybe an organic responsive reaction under the chronic liver fibrosis.Excessive activation of HOC may lead to cancer.
引文
[1]高春芳,陆伦根.纤维化疾病的基础和临床[M].上海.上海科技出版社.2004:299
[2]Rockey DC,Chung JJ.Interferon gamma inhibits lipocytes activation and extracellularm atrix mRNA expression during experimental liver injury:implication of hepatic fibrosis[J].J Invest Med,1994,42(3):660-670
[3]Davis BH,Rapp UR,and Davidson N.Retinoic acid and transforming Growth factor beta differentially inhibit platelet-derived-growth factor-induced Ito-cell activation[J].Biochem J,1991,278(1):43-47
[4]程明亮,刘三都.肝纤维化的基础研究与临床[M].北京.人民卫生出版社.1996:106-107
[5]肖家诚,金晓龙,曾晓颖,等.肝细胞肝癌和肝硬化组织中的卵圆细胞:电镜与免疫电镜研究.检验医学,2004,19(1):47-50
[6]Xiao JC,Jin XL,Ruck p,et al.Hepatic progenitor cells in human liver cirrhosis:immunohistochemical,electronmicroscopic and immunofluorence confocal microscopic findings.World J Gastroenterol.2004 Apr 15;10(8):1208-11
[7]邱德凯,马雄,彭延申,等.慢性肝病患者肝卵圆细胞的定位和定量研究—29例慢性肝病患者肝组织病理学分析[J].中华消化杂志,2000,20(5):301-303
[8]Farber E.Similiarities in the sequence of early histologic changes induced in the livers of rats by ethionine,2-acetylaminofluorene and 3-methyl-4-dimethy laminoazobenzene.Cancer Res 1956;16:142-148
[9]Forbess S,Vig P,Poulsom R,et al.Hepatic stem cell.[J].pathology,2002,197:510-518
[10]Michalopoulos G.Liver regeneration,medecular mechanism of growth control.Faseb J.1999,4,176-187
[11]Cassiman D,Libbrecht L,Sinelli N,et al.The vagal nerve stimulates activation of the hepatic progenitor cell compartment via muscarinic acetylcholine receptor type 3.Am J Pathol 2002,161(2):521-30
[12]Oben JA,Roskams T,Yang S,et al.Sympathetic nervous system inhibition increases hepatic progenitors and reduces liver injury.Hepatology 2003,38(3):664-73
[13]王新禾,张锦生,张秀荣,等.四氯化碳诱导大鼠肝纤维化肝内细胞蛋白骨架表达的变化.上海医科大学学报,1998,25(4):254
[14]Chen Xiaoyin,Li Enqing,Yang Qinhe,et al.Clinical study of Dahuang Zhechong Pill in treating posthepatitis B hepatic fibrosis.CJIM,2004(10)1:63-65
[15]龙庆华,喻晓锋,欧阳红,等.大黄蟅虫丸抗纤维化临床分析.江西中医药,2001(32)3:21
[16]喻长远,陈珍贵,田永立,等.大黄蟅虫丸对大鼠两种肝纤维化模型的影响.中国中医基础医学杂志,2002,8(12):33-34
[17]任小巧,卢跃卿,陈永旭,等.仲景三方对大鼠肝纤维化不同时期胶原Ⅰ、Ⅲ、Ⅳ影响的观察.中国中医杂志.2001,26(4):266-268
[18]李岚生,徐曼,刘志龙,等.大黄蟅虫丸对大鼠肝星状细胞表达TGF-β_1的影响.中国中西医结合杂志.2003;23(10):763-766
[19]李亮,月辰,缪英年.祖国医学对肝纤维化的认识探析[J].实用中医内科杂志.2004,18(4):281-282
[20]病毒性肝炎中医辨证标准(试行)[S].中医杂志,1992,33(5):39-40
[21]危北海,张育轩.肝硬化临床诊断中医辨证和疗效评定标准(试行)[S].中国中西医结合杂志,1994,14(4):237-238.
[22]郑莜萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:147-148
[23]张俊富,崔丽安.慢性肝炎与肝硬化辨证分型与血清肝纤维化指标的关系[J].中西医结合肝病杂志,1995,5(4):10
[24]潘志恒,陈琰碧,邓子德,等.慢性肝炎及肝硬化患者中医证型与血清肝纤维指标的关系[J].中医杂志,1999,40(8):459
[25]钱海青.辨证治疗肝炎后肝纤维化[J].浙江中医杂志.1999.15(8):558.
[26]李筠.中医证型与肝炎患者血清肝纤维化指标及肝脏病理关系的研究[J].新中医,1999,3 1(2):36-37.
[27]薛博瑜,顾学兰.肝纤维化的病机认识和辨证论治[J].南京中医药大学学报,2001,7(2):76
[28]夏永良,崔家鹏.李德新治疗肝纤维化经验[J].中医杂志,2003,44(5):3381
[29]陈建明,赵冬,强世平,等.水蛭桃仁汤对实验性肝纤维化大鼠血清Ⅰ、Ⅲ型前胶原水平的影响.中国全科医学杂志,1998,1(3):165-167
[30]晏丹,茹清静,朱起贵.论肝血瘀阻与肝纤维化的关系.中国中医基础医学杂志,1996,2(3):14-15
[31]邝卫红.鳖甲煎汤抗肝纤维化的血清学研究[J].广州中医药大学学报,2004,21(6):420-423
[32]黄彬,周大桥,高辉,等.软肝冲剂治疗肝纤维化的临床研究[J].新中医,2000,32(10):34-35
[33]于世瀛,贲长恩,杨美娟,等.清热利湿方药抗肝纤维化的形态学和免疫组织化学定量研究.北京中医药大学学报,1997,20(1):28
[34]郑元义,戴立里,王文兵,等.丹参素治疗肝纤维化及其作用机制研究[J].中华肝脏病杂志,2003,5(11):5
[35]马学惠,赵元昌,尹镭,等.丹参对肝纤维化的重吸收作用.中国中西医结合杂志,1986,8(3):161-3
[36]吴炎,田怡,陈建文,等.黄芪注射液对肝硬化肝功能的影响[J].中国中西医结合杂志,1999,19(6):363
[37]马红,于宝恩,陈翌阳,等.黄芪对免疫损伤性肝纤维化大鼠的治疗作用.中西医结合肝病杂志,1997,7(1):32-5
[38]牛家璇,王宝恩,王泰玲,等.冬虫夏草对实验性免疫损伤性肝纤维化的预防和治疗作用研究[J].中华消化杂志,1994,14(6):333-335
[39]张荣华,周子成,洪多伦,等.三七抗肝纤维化的实验研究[J].第三军医大 学学报,2000,22(4):307.
[40]李延昌,孙玉风,冯志杰,等.赤芍抗肝纤维化的实验研究[J].中国中西医结合杂志,2003,23(10):767.
[41]王胜春,王玲.柴胡及五灵丸对慢性肝损伤小鼠的影响[J].第四军医大学学报,2002,23(2):133
[42]王萍,陈青莲.柴胡炮制品对小白鼠全血胆碱醋酶活力的影响[J].中药材,2000,3(4):219.
[43]陈爽,责长恩,杨美娟.柴胡皂甙对肝细胞增殖及基质合成的实验研究[J].中国中医基础医学杂志.1999,5(5):21-25
[44]Shi MI.Sho-Saiko-to:Japanese verbal medicine for protection against hepatic fibrosis and carcinoma[J].J Gastroenterol Hepatol,2000,15(3):84-90.
[45]权启镇,孙自勤,李定国,等.钙拮抗剂抗肝纤维化的实验和临床研究.新消化病学杂志,1994,2(4):214-7
[46]范列英,孔涛,高锋,等.汉防己甲素对成纤维细胞人胎肝细胞DNA及胶原合成的影响.临床肝胆病杂志,1995,11(1):25-6
[47]陈岳祥,李石,张兴荣,等.牛磺酸对四氯化碳诱导大鼠肝纤维化的抑制作用[J].中华消化杂志,1999,19(3):185.
[48]陈伟忠,张俊平,许青,等.苦参碱对大鼠实验性肝纤维化的影响.第二军医大学学报,1996,17(5):424-6
[49]李晓清,陆洋,郝丽萍.等.苦参素注射液抗肝纤维化的临床疗效观察.胃肠病学和肝病学杂志.2001,10(2):187-9
[50]徐列明,刘成,刘平,等.桃仁提取抗实验性肝纤维化的作用观察中国中药杂志,1994,19(8):491
[51]徐列明,刘成,刘平,等.桃仁提取抗肝窦毛细血管化的实验研究.肝脏病杂志.1993,1(2):73-6
[52]王吉耀,刘维田,胡美玉,等.甘草酸对成纤维细胞Ⅰ、Ⅲ型前胶原mRNA 表达的抑制作用.中华消化杂志,1997,17(1):60-615
[53]王吉耀,郭津生,刘淑玲,等.甘草酸对肝硬化动物模型肝脏内NF-kB结合活性的抑制作用.中华肝脏病杂志,1999;7(1):42-43
[54]张其胜.甘草酸对肝纤维化Ito细胞Ⅰ、Ⅲ型前胶原mRNA表达和胶原沉积的影响.中华肝脏病杂志,1999,7(3):164.
[55]蔺武,刘心娟.复方鳖甲软肝片抗肝纤维化疗效的系统评价[J].胃肠病学和肝病学杂志,2007,16(1):69-71
[56]王宝恩.活血化淤中药复方对实验性肝纤维化的疗效观察.中草药,1990.(4):23
[57]刘平,胡义扬,徐列明,等.扶正化淤319方抗大鼠肝纤维化的研究·中国实验方剂学杂志,1997,3(4):20
[58]姚欣,姚希贤,孙泽明,等.强肝胶囊对大鼠试验性肝纤维化防治作用.胃肠病学和肝病学杂志,2001,10(3):223-6
[59]姜学连,韩业坤,邢日利,等.慢肝合剂促进大鼠肝细胞再生实验研究[J].中国中医急症,2005,14(1):64-65.
[60]王丽春,赵连三,唐红,等.温阳中药复方肝之福逆转肝纤维化的实验研究[J].中国中西医结合杂志,2006,26(1):63-67.
[61]刘成,姜春萌,刘平.扶正化瘀方对大鼠HSC旁分泌活化途径抑制作用[J].中华消化杂志,2001,21(6):367-369
[62]文彬,彭齐荣,贺松其.清香散对肝纤维化大鼠转化生长因子β_1及Smad4免疫组化的影响[J].江苏中医药,2006,27(3):55-57.
[63]杨柳明,徐克成,赵廷龙,等.强肝胶囊治疗慢性乙型肝炎肝纤维化的临床病理研究.胃肠病学和肝病学杂志,2001,10(3):247-9
[64]王宝恩.肝纤维化的中医中药治疗.中华肝脏病杂志,2001,9(2):120-1
[65]刘平.扶正化淤319方治疗慢性乙型肝炎及其对肝纤维化血清学指标的影响.中国中西医结合杂志,1996,16(10):388
[66]杨宏志.补肾益气凉血活血解毒法治疗肝纤维化近期疗效观察.中医杂志,1998,39(6):34
[67]燕忠生,沈吉云.软肝合剂联合干扰素治疗乙肝后肝纤维化25例临床研究[J].中医杂志,2002,43(10):753-754
[68]陈汉诚,翁伦华.黄芪首乌化纤汤与金水宝胶囊抗乙型肝炎纤维化疗效比较[J].中国中西医结合杂志,2000,20(4):255-257
[69]宋家武,李绍白,张文英.血府逐淤汤抗大鼠肝纤维化作用的研究.中西医结合肝病杂志,1997,7(1):38
[70]魏常胜,王宇,薛建国,等.丹柴四君子汤对大鼠肝硬化中肝线粒体保护作用的实验研究[J].中华肝胆外科杂志,2004,10(9):623-626.
[71]Sakea A.小柴胡汤和大柴胡汤对大鼠实验性肝纤维化的影响.国外医学中医中药分册,1989;11(4):28
[72]曾凡波,晏菊姣,万波,等.鳖甲煎丸药理学研究[J].中成药,2002,24(7):529-532
[73]陈廷玉,卢春凤,清云,等.茵陈蒿汤对实验性肝纤维化大鼠肝细胞的保护作用及超微结构观察[J].黑龙江医药科学,2004,27(1):11-12
[74]Albanis E,Friedman SL.Hepatic fibrosis.Pathogenesis and principles of therapy[J].ClinLiverDis,2001,5(2):315-334.
[75]Lamireau T,Desmouliere A,Bioulac-Sage P,et al.Mechanisms of hepatic fibrogenesis[J].Arch Pediatr,2002,9(4):392-405.
[76]Thompson KC,Maltby J,Fallowfield J,et al.Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis[J].Hepatology,1998,28(6):1597-1606.
[77]Forbess S,Vig P,Poulsom R,et al.Hepatic stem cell[J],J Pathology,2002,197:510-518.
[78]Thorgeirsson SS.Hepatic stem cells in liver regeneration.FASEB J,1996,10:1249-1256.
[79]Wang X,Foster M,Al-dhalimy M,et al.The origin and liver repopulation capacity of murine oval cells.Proc Natl Acad Sci USA 2003,30;100 Supple 1:11881-8
[80]Sandor R Janos S,Peter N.et al.Origin and structural evolution of early proliferating oval cells in rat liver.[J].Am J Pathal,2001,158(4):1313-1323
[81]陈耀凯,王宇明,李俊刚等.大鼠肝卵圆细胞的形态及免疫学组织化学特征研究.中华试验外科杂志[J].Chain J Exp Su唱,January 2003.20(1):85-86
[82]Peterdsen BE,Bowen WC,Patrenke,et al.Bone Marrow as a potential source of hepatic oval cells.Science,1999,28(4):1168-1170
[83]Malcolm R,Richard J,Rosemar J,et al.Hepatocytes from nonhepatic adult stem cells.Nature[J],2000,406:257
[84]Xiao JC,Ruck P,Adam A,et al.The Origin and liverrepopulation capacity of murine oval cells.Proc Natl Acid Sci USA.2003 30;100 Suppl 1:11881-8
[85]Tan J,Hytiroglou P,Wiezzorek P,et al.Immunohistochemical evidence for hepatic progentor cells.Histopathology,2003;42(2):141-9
[86]Max,Qiu DK,Peng YS.Immunohistochemical study of hepatic oval cells in human chronic vital hepatitis.World J Gastroenterol.2001;7(2):238-42
[87]Domingu ez-malagon H,Gaytan-Graham S.Hepatocellular carcinoma:an update.Ultrastruct Pathol.2001;25(6):497-516
[88]Fang CH,Zhang W,Zhu XY,et al.The expression of c-kit and proliferating cell nucleur antigen in oval cells of rats with hepatocellulaet carcinama.Hepatobiliary Pancreat Dis Int.2003;2(4):537-44
[89]Lowes KN,Brennan BA,Yeoh Gc et al.Oval cell numbers in human chronic liver diseases are directly related to disease severity.Am J Pathol,1999,154:537-541?
[90]Thorgeirsson SS,Factor VM,Synderwine EG.Transgenic mouse moels in carsinogenesis research and testing.Toxicol letl 2000,112-113:553-555
[91]Libbrecht L,Meerman L,Kuipers F,er al.Liver pathology and hepatocvarcinogenesis in a long term mouse model of evythropropoietic protoporphyria.[J]Pathol 2003,199:191-200
[92]Hsia CC,Evarts RP,Nakatsukasa H,et al.Occurrence of oval-type cells in hepatitis B virus-assaciated human hepatocarcinogenesis.Hepatology 1997,16:1327-1333
[93]Tania Roskams, Shi QiYang.Aymen Koteish, et al.Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease.American Journal of Pathololy.2003 .163(4): 1301-1311
[94]Michalopoulos G.Liver regeneration molecular mechanism of growth of growth ontrol.Faseb J, 4.1990, 176-187
[95]Okano J, Shiota G, Matsumoto K, et al.Hepatocy growth factor exerts a proliferative effect on oval cells through the PI3K/AKT signaling pathway.Biochem biophys res commun.2003 19; 309(2): 298-304
[96]Sautin YY, Jorgensen M, Petersen BE, et al.Hepatic oval cell expression of endothelial differentiation gene receptors for lysophosphetidic acid in mouse chronic liver injury.[J]Hematother stem cell Res, 2002.11(4): 643-9
[97]Libbrecht L, Roskams T.Hepatic progenitor cells in human liver diseases.Semin cell dev boil.2002; 13(6): 389-96
[98]Hatch HM, Zheng D, Jorgensen ML, et al.SDF-lalpha/CXCR4: a mechanism for hepatic oval cell activation and bone marrow stem cell recruitment to the injuried liver of rats.Cloning stem cells.2002; 4(4): 339-51
[99]Chen JZ, Hang H, Xiang J, et al.A selective tropism of transfused oval cells for liver.World J Gastroenterol.2003; 9(3): 544-6
[100]Oh SH, Hatch HM, Petersen BE.Hepatic oval stem cell in liver regeneration.Semin cell dev boil.2002; 13(6): 405-9
[101]He ZP, Tan WQ, Tang YF, et al.Differentiation of putative hepatic stem cell derived from adult rats into mature hepatocytes in the presence of epidermal growth factor and hepatocyte growth factor.Differentiation.2003,71(45): 287-90
[102]Petersen BE, Grossbard B, Hatch H, et al.Mouse A6-positive hepatic oval cells also express several hematopoietic stem cell markers.Hepatology.2003, 37(3): 625-40
[103]Kumar KS, Lefkowitch J.Russo MW, et al.Successful sequential liver and stem cell transplantation for hepatic failture due to primary Alamyloidosis.Gastroenterology, 2002, 122: 2026-2031
[104]Tordoff GM,Novin D.Celiac vagotomy attenuates the ingestive responses to epinephrine and hypertonic saline but not insulin,2-deoxy-D-glucose,or polyethylene glycol[J].Physiol Behav,1982,29(4):605-613.
[105]Akiyoshi H,Gonda T,Terada T.A comparative histochemical and immunohisto-chemical study of aminergic,cholinergic and peptidergic innervation in rat,hamster,guinea pig,dog and human livers[J].Liver,1998,18(5):352-359.
[106]Fukuda Y,Imoto M,Koyama Y,et al.Demonstration of noradrena-line-immunoreactive nerve fibres in the liver[J].J Int Med Res,1996,24(6):466-472.
[107]HuangQH,Takaki A,Arimura A.Central noradrenergic systemrnodulats plasma interleukin-6 production by peripheral interleukin-1[J].Am J Physiol.1997,273(2 Pt2):R731-738.
[108]Haeusler G.Early pre-post junctional effects of 6-hydroxydopamine[J].J Phar macol Exp Ther,1971,178(1):49-62.
[109]Matsuda Y,Matsumoto K,Yamada A,Ichida T,Asakura H,Komoriya-Y,Nishiyama E,Nakamura T.Preventive and Therapeutic Effects in Rats of Hepatocyte Growth Factor Infusion on Liver Fibrosis/ Cirrhosis.Hepatology 1997;26:81-89
[110]中华医学会传染病与寄生虫病学分会,肝病学分会联合修订.病毒性肝炎防治方案.中华肝脏病杂志,2000,8:324-9
[111]Alison MR,Poulsom R,Forbes SJ.Update on hepatic stem cells[J].Liver,2001,21(6):367-373.
[112]金树根,王灵台,任家淮,等.二甲基亚硝胺致大鼠肝纤维化的造模研究[J].中西医结合肝病杂志,1994,4(1):28-30.
[113]George J,Chandrakasan G.Lactate dehydrogenase isoenzymes in dimethylnitro-samine induced hepatic fibrosis in rats[J].J clin Biochem Nutr,1997,22:51-52.
[114]Shiba M,Shimizu I,Yaauda M,et al.Expression of type I and type IV collagens during the courseof dimethylnitrosamine induced hepatic fibrosis in rats[J].Liver,1998,18:196-200.
[115]Tsursumi M,Urashima S,Nakase Ket al.Change in laminin content in livers of patients with alcoholic liver disease.Liver,1995;15(6):324-31.
[116]Dunsford HA,Sell S.Production of monoclonal antibodies to preneoplastic liver cell populations induced by chemical carcinogens in rats and to transplantable Morris hepatomas[J].Cancer Res,1989,49(17):4887-4893.
[117]Silva GV,Litovsky S,Assad JA.et al.Mesenchymal stem cells differentiate into an endothelial phenotype,enhance vascular density,and improve heart function in a canine chronic ischemia model.Circulation 2005:111(2):150-156.
[118]Grompe M.Adult versus embryonic stem cells:It's still a tie.Mol Ther,2002.6:303-305.
[119]Jude A.Oben et al.Sympathetic Nervous System Inhibition Increases Hepatic Progenitors and Reduces Liver Injury.HEPATOLOGY,2003,38(3):664-673
[120]Jude A.Oben and Anna Mae Diehl.Sympathetic Nervous System Regulation of Liver Repair.THE ANATOMICAL RECORD PART A 280A:874-883
[121]KimH,Booth CJ,PinusAB,et al.Induced hepatic fibrosis in rats:hepatic steatosis,macromolecule content,perfusion parameters,and their correlations—preliminary MR imaging in rats[J].Radiology,2008,247(3):696-705.
[122]Flisiak R,Maxwell P,Prokopowicz D,etal.Plasma tissue inhibitor of metallo-proteinases-1and transforming growth factor beta 1—possible non-invasive biomarkers of hepatic fibrosis in patients with chronic B and C hepatitis[J].Hepato-gastroenterology,2002,49(47):1369-1372.
[123]Chandru H,Sharada AC,Manjunath S.Expression of matrix metalloproteinase (MMP-2)and extracellular matrix metalloproteinases inducer(EMMPRIN)in benign and advanced breast cancer tissue samples[J].Biomed Khim,2007.53(4):461-467.
[124]KornekM,Raskopf E,Guetgemann I,et al.Combination of systemic thioacetamide(TAA)injections and ethanol feeding accelerates hepatic fibrosis in C3H/He mice and is associated with intrahepatic up regulation of MMP-2,VEGF and ICAM-1[J].J Hepatol,2006,45(3):370-376.
[125]吴其恺,杨大国,陶艳艳,等.正肝化瘀方对肝纤维化大鼠肝组织MMPs和TIMPs蛋白表达的影响[J].中西医结合肝病杂志,2008,18(1):35-37.
[126]Goto T,Mikami KI,Miura K,et al.Department of Gastroenterology, Mechanical stretch induce smatrixmetalloproteinasel production in human hepatic stellate cells[J].Pathophysiology,2004,1 l(3):153-158.
[127]Abe S,Amagasaki Y,Lyori S,et al,Significance of tubuloint-erstitial lesions in biopsy specimens of glomerulonephritic ptients[J].Am J Nephrol Hypertents,1989,9:30
[128]Ryseck RP,Macdonld-Bravo H,Mattei MG,et al.Structure,mapping,and expression of fisp-12,a growth factor-inducible gene encoding a screted cysteine-rich protein[J].Cell GrowthDiffer,1991,2:225-233.
[129]Weng HL,Ciuclan L,Liu Y,Hamzavi J,Godoy P,Gaitantzi H,Kanzler S,Heuchel R,Ueberham U,Gebhardt R,Breitkopf K,Dooley S.Profibrogenic transforming growth factor-beta/activin receptor-like kinase 5 signaling via connective tissue growth factor expression in hepatocytes.Hepatology 2007;46:1257-1270
[130]GressnerAM,Weiskirchen R,BreitkoptK,et al Roles ofrGF-beta in hepatic fibrosis[J].FrontBiosc,i 2002,7:d793-807.
[131]Blom IE,Goldschmeding R,Leask A.Gene regulation of connective tissue growth factor:new targets for antifibrotic therapy?[J].Matrix Biol,2002,21(6):473.
[132]牟善初,赵海潞.老年肾问质纤维化时转化生长因子β_1的免疫电镜观察.解放军医学杂志,2000,25(6):434
[133]Dooley S,Delvoux B,Streckert Met al.Transforming growth factor beta signal transduction in hepatic stellate cells via Smad2/3 phosphorylation,a pathway that isabrogated duringin vitroprogression to myofibroblasts.TGFbeta signal transduction during transdifferentiation of hepatic stellate cells.FEBS Lett,2001,502(1-2):4
[134]Yamatani T,Kobayashi H,Tezuka Ket al.Establishment of the enzyme linked immunosorbent assay for connective tissue growth factor(CTGF)and its detection in the sera of biliary atresia.Biochem Biophys Res Commun,1998,251(3):748
[135]Paradis V,Dargere D,Bonvoust Fet al.Effectsand regulation of connective tissue growth factor on hepatic stellate cells.Lab Invest,2002.82(6):767
[136]Saegusa S,Isaji S,Kawarada Y.Changes in serum hyaluronic acid levels and expression of CD44 and CD44 mRNA in hepatic sinusoidal endothelial cells after major hepatectomy in cirrhotic rats[J].World J Surg,2002,26(6):694.
[137]赵丽娟,李红,杨世杰,等.黄芪注射液对D-半乳糖胺所致小鼠急性肝损伤的保护作用[J].吉林大学学报:医学版,2003.29(3):280-282
[138]Hansson EM,Lendahl U,Chapman G.Notch signaling in development and disease.Semin Cancer Biol,2004,14(5):320-328.
[139]Henrique D,HirsingerE,Adam J,et a.1 Maintenance of neuroepi thelial progenitor cells by Delta-Notch signaling in the embryonic chick retina[J].CurrBio,1 1997,7(9):661-670.
[140]Iwata M,Awaya N,Graf L,et al.Human marrow stromal cells activate monocytes to secrete osteopontin,which down regulates Notch 1 gene expression in CD34+cells.Blood,2004,103(12):4496-4502.
[141]Bicknell R,Harris AL.Novel angiogenic signaling pathways and vascular targets.Annu Rev Pharmacol Toxicol,2004,44:219-238.
[2]Rockey DC,Chung JJ.Interferon gamma inhibits lipocytes activation and extracellularm atrix mRNA expression during experimental liver injury:implication of hepatic fibrosis[J].J Invest Med,1994,42(3):660-670
[3]Davis BH,Rapp UR,and Davidson N.Retinoic acid and transforming Growth factor beta differentially inhibit platelet-derived-growth factor-induced Ito-cell activation[J].Biochem J,1991,278(1):43-47
[4]程明亮,刘三都.肝纤维化的基础研究与临床[M].北京.人民卫生出版社.1996:106-107
[5]肖家诚,金晓龙,曾晓颖,等.肝细胞肝癌和肝硬化组织中的卵圆细胞:电镜与免疫电镜研究.检验医学,2004,19(1):47-50
[6]Xiao JC,Jin XL,Ruck p,et al.Hepatic progenitor cells in human liver cirrhosis:immunohistochemical,electronmicroscopic and immunofluorence confocal microscopic findings.World J Gastroenterol.2004 Apr 15;10(8):1208-11
[7]邱德凯,马雄,彭延申,等.慢性肝病患者肝卵圆细胞的定位和定量研究—29例慢性肝病患者肝组织病理学分析[J].中华消化杂志,2000,20(5):301-303
[8]Farber E.Similiarities in the sequence of early histologic changes induced in the livers of rats by ethionine,2-acetylaminofluorene and 3-methyl-4-dimethy laminoazobenzene.Cancer Res 1956;16:142-148
[9]Forbess S,Vig P,Poulsom R,et al.Hepatic stem cell.[J].pathology,2002,197:510-518
[10]Michalopoulos G.Liver regeneration,medecular mechanism of growth control.Faseb J.1999,4,176-187
[11]Cassiman D,Libbrecht L,Sinelli N,et al.The vagal nerve stimulates activation of the hepatic progenitor cell compartment via muscarinic acetylcholine receptor type 3.Am J Pathol 2002,161(2):521-30
[12]Oben JA,Roskams T,Yang S,et al.Sympathetic nervous system inhibition increases hepatic progenitors and reduces liver injury.Hepatology 2003,38(3):664-73
[13]王新禾,张锦生,张秀荣,等.四氯化碳诱导大鼠肝纤维化肝内细胞蛋白骨架表达的变化.上海医科大学学报,1998,25(4):254
[14]Chen Xiaoyin,Li Enqing,Yang Qinhe,et al.Clinical study of Dahuang Zhechong Pill in treating posthepatitis B hepatic fibrosis.CJIM,2004(10)1:63-65
[15]龙庆华,喻晓锋,欧阳红,等.大黄蟅虫丸抗纤维化临床分析.江西中医药,2001(32)3:21
[16]喻长远,陈珍贵,田永立,等.大黄蟅虫丸对大鼠两种肝纤维化模型的影响.中国中医基础医学杂志,2002,8(12):33-34
[17]任小巧,卢跃卿,陈永旭,等.仲景三方对大鼠肝纤维化不同时期胶原Ⅰ、Ⅲ、Ⅳ影响的观察.中国中医杂志.2001,26(4):266-268
[18]李岚生,徐曼,刘志龙,等.大黄蟅虫丸对大鼠肝星状细胞表达TGF-β_1的影响.中国中西医结合杂志.2003;23(10):763-766
[19]李亮,月辰,缪英年.祖国医学对肝纤维化的认识探析[J].实用中医内科杂志.2004,18(4):281-282
[20]病毒性肝炎中医辨证标准(试行)[S].中医杂志,1992,33(5):39-40
[21]危北海,张育轩.肝硬化临床诊断中医辨证和疗效评定标准(试行)[S].中国中西医结合杂志,1994,14(4):237-238.
[22]郑莜萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:147-148
[23]张俊富,崔丽安.慢性肝炎与肝硬化辨证分型与血清肝纤维化指标的关系[J].中西医结合肝病杂志,1995,5(4):10
[24]潘志恒,陈琰碧,邓子德,等.慢性肝炎及肝硬化患者中医证型与血清肝纤维指标的关系[J].中医杂志,1999,40(8):459
[25]钱海青.辨证治疗肝炎后肝纤维化[J].浙江中医杂志.1999.15(8):558.
[26]李筠.中医证型与肝炎患者血清肝纤维化指标及肝脏病理关系的研究[J].新中医,1999,3 1(2):36-37.
[27]薛博瑜,顾学兰.肝纤维化的病机认识和辨证论治[J].南京中医药大学学报,2001,7(2):76
[28]夏永良,崔家鹏.李德新治疗肝纤维化经验[J].中医杂志,2003,44(5):3381
[29]陈建明,赵冬,强世平,等.水蛭桃仁汤对实验性肝纤维化大鼠血清Ⅰ、Ⅲ型前胶原水平的影响.中国全科医学杂志,1998,1(3):165-167
[30]晏丹,茹清静,朱起贵.论肝血瘀阻与肝纤维化的关系.中国中医基础医学杂志,1996,2(3):14-15
[31]邝卫红.鳖甲煎汤抗肝纤维化的血清学研究[J].广州中医药大学学报,2004,21(6):420-423
[32]黄彬,周大桥,高辉,等.软肝冲剂治疗肝纤维化的临床研究[J].新中医,2000,32(10):34-35
[33]于世瀛,贲长恩,杨美娟,等.清热利湿方药抗肝纤维化的形态学和免疫组织化学定量研究.北京中医药大学学报,1997,20(1):28
[34]郑元义,戴立里,王文兵,等.丹参素治疗肝纤维化及其作用机制研究[J].中华肝脏病杂志,2003,5(11):5
[35]马学惠,赵元昌,尹镭,等.丹参对肝纤维化的重吸收作用.中国中西医结合杂志,1986,8(3):161-3
[36]吴炎,田怡,陈建文,等.黄芪注射液对肝硬化肝功能的影响[J].中国中西医结合杂志,1999,19(6):363
[37]马红,于宝恩,陈翌阳,等.黄芪对免疫损伤性肝纤维化大鼠的治疗作用.中西医结合肝病杂志,1997,7(1):32-5
[38]牛家璇,王宝恩,王泰玲,等.冬虫夏草对实验性免疫损伤性肝纤维化的预防和治疗作用研究[J].中华消化杂志,1994,14(6):333-335
[39]张荣华,周子成,洪多伦,等.三七抗肝纤维化的实验研究[J].第三军医大 学学报,2000,22(4):307.
[40]李延昌,孙玉风,冯志杰,等.赤芍抗肝纤维化的实验研究[J].中国中西医结合杂志,2003,23(10):767.
[41]王胜春,王玲.柴胡及五灵丸对慢性肝损伤小鼠的影响[J].第四军医大学学报,2002,23(2):133
[42]王萍,陈青莲.柴胡炮制品对小白鼠全血胆碱醋酶活力的影响[J].中药材,2000,3(4):219.
[43]陈爽,责长恩,杨美娟.柴胡皂甙对肝细胞增殖及基质合成的实验研究[J].中国中医基础医学杂志.1999,5(5):21-25
[44]Shi MI.Sho-Saiko-to:Japanese verbal medicine for protection against hepatic fibrosis and carcinoma[J].J Gastroenterol Hepatol,2000,15(3):84-90.
[45]权启镇,孙自勤,李定国,等.钙拮抗剂抗肝纤维化的实验和临床研究.新消化病学杂志,1994,2(4):214-7
[46]范列英,孔涛,高锋,等.汉防己甲素对成纤维细胞人胎肝细胞DNA及胶原合成的影响.临床肝胆病杂志,1995,11(1):25-6
[47]陈岳祥,李石,张兴荣,等.牛磺酸对四氯化碳诱导大鼠肝纤维化的抑制作用[J].中华消化杂志,1999,19(3):185.
[48]陈伟忠,张俊平,许青,等.苦参碱对大鼠实验性肝纤维化的影响.第二军医大学学报,1996,17(5):424-6
[49]李晓清,陆洋,郝丽萍.等.苦参素注射液抗肝纤维化的临床疗效观察.胃肠病学和肝病学杂志.2001,10(2):187-9
[50]徐列明,刘成,刘平,等.桃仁提取抗实验性肝纤维化的作用观察中国中药杂志,1994,19(8):491
[51]徐列明,刘成,刘平,等.桃仁提取抗肝窦毛细血管化的实验研究.肝脏病杂志.1993,1(2):73-6
[52]王吉耀,刘维田,胡美玉,等.甘草酸对成纤维细胞Ⅰ、Ⅲ型前胶原mRNA 表达的抑制作用.中华消化杂志,1997,17(1):60-615
[53]王吉耀,郭津生,刘淑玲,等.甘草酸对肝硬化动物模型肝脏内NF-kB结合活性的抑制作用.中华肝脏病杂志,1999;7(1):42-43
[54]张其胜.甘草酸对肝纤维化Ito细胞Ⅰ、Ⅲ型前胶原mRNA表达和胶原沉积的影响.中华肝脏病杂志,1999,7(3):164.
[55]蔺武,刘心娟.复方鳖甲软肝片抗肝纤维化疗效的系统评价[J].胃肠病学和肝病学杂志,2007,16(1):69-71
[56]王宝恩.活血化淤中药复方对实验性肝纤维化的疗效观察.中草药,1990.(4):23
[57]刘平,胡义扬,徐列明,等.扶正化淤319方抗大鼠肝纤维化的研究·中国实验方剂学杂志,1997,3(4):20
[58]姚欣,姚希贤,孙泽明,等.强肝胶囊对大鼠试验性肝纤维化防治作用.胃肠病学和肝病学杂志,2001,10(3):223-6
[59]姜学连,韩业坤,邢日利,等.慢肝合剂促进大鼠肝细胞再生实验研究[J].中国中医急症,2005,14(1):64-65.
[60]王丽春,赵连三,唐红,等.温阳中药复方肝之福逆转肝纤维化的实验研究[J].中国中西医结合杂志,2006,26(1):63-67.
[61]刘成,姜春萌,刘平.扶正化瘀方对大鼠HSC旁分泌活化途径抑制作用[J].中华消化杂志,2001,21(6):367-369
[62]文彬,彭齐荣,贺松其.清香散对肝纤维化大鼠转化生长因子β_1及Smad4免疫组化的影响[J].江苏中医药,2006,27(3):55-57.
[63]杨柳明,徐克成,赵廷龙,等.强肝胶囊治疗慢性乙型肝炎肝纤维化的临床病理研究.胃肠病学和肝病学杂志,2001,10(3):247-9
[64]王宝恩.肝纤维化的中医中药治疗.中华肝脏病杂志,2001,9(2):120-1
[65]刘平.扶正化淤319方治疗慢性乙型肝炎及其对肝纤维化血清学指标的影响.中国中西医结合杂志,1996,16(10):388
[66]杨宏志.补肾益气凉血活血解毒法治疗肝纤维化近期疗效观察.中医杂志,1998,39(6):34
[67]燕忠生,沈吉云.软肝合剂联合干扰素治疗乙肝后肝纤维化25例临床研究[J].中医杂志,2002,43(10):753-754
[68]陈汉诚,翁伦华.黄芪首乌化纤汤与金水宝胶囊抗乙型肝炎纤维化疗效比较[J].中国中西医结合杂志,2000,20(4):255-257
[69]宋家武,李绍白,张文英.血府逐淤汤抗大鼠肝纤维化作用的研究.中西医结合肝病杂志,1997,7(1):38
[70]魏常胜,王宇,薛建国,等.丹柴四君子汤对大鼠肝硬化中肝线粒体保护作用的实验研究[J].中华肝胆外科杂志,2004,10(9):623-626.
[71]Sakea A.小柴胡汤和大柴胡汤对大鼠实验性肝纤维化的影响.国外医学中医中药分册,1989;11(4):28
[72]曾凡波,晏菊姣,万波,等.鳖甲煎丸药理学研究[J].中成药,2002,24(7):529-532
[73]陈廷玉,卢春凤,清云,等.茵陈蒿汤对实验性肝纤维化大鼠肝细胞的保护作用及超微结构观察[J].黑龙江医药科学,2004,27(1):11-12
[74]Albanis E,Friedman SL.Hepatic fibrosis.Pathogenesis and principles of therapy[J].ClinLiverDis,2001,5(2):315-334.
[75]Lamireau T,Desmouliere A,Bioulac-Sage P,et al.Mechanisms of hepatic fibrogenesis[J].Arch Pediatr,2002,9(4):392-405.
[76]Thompson KC,Maltby J,Fallowfield J,et al.Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis[J].Hepatology,1998,28(6):1597-1606.
[77]Forbess S,Vig P,Poulsom R,et al.Hepatic stem cell[J],J Pathology,2002,197:510-518.
[78]Thorgeirsson SS.Hepatic stem cells in liver regeneration.FASEB J,1996,10:1249-1256.
[79]Wang X,Foster M,Al-dhalimy M,et al.The origin and liver repopulation capacity of murine oval cells.Proc Natl Acad Sci USA 2003,30;100 Supple 1:11881-8
[80]Sandor R Janos S,Peter N.et al.Origin and structural evolution of early proliferating oval cells in rat liver.[J].Am J Pathal,2001,158(4):1313-1323
[81]陈耀凯,王宇明,李俊刚等.大鼠肝卵圆细胞的形态及免疫学组织化学特征研究.中华试验外科杂志[J].Chain J Exp Su唱,January 2003.20(1):85-86
[82]Peterdsen BE,Bowen WC,Patrenke,et al.Bone Marrow as a potential source of hepatic oval cells.Science,1999,28(4):1168-1170
[83]Malcolm R,Richard J,Rosemar J,et al.Hepatocytes from nonhepatic adult stem cells.Nature[J],2000,406:257
[84]Xiao JC,Ruck P,Adam A,et al.The Origin and liverrepopulation capacity of murine oval cells.Proc Natl Acid Sci USA.2003 30;100 Suppl 1:11881-8
[85]Tan J,Hytiroglou P,Wiezzorek P,et al.Immunohistochemical evidence for hepatic progentor cells.Histopathology,2003;42(2):141-9
[86]Max,Qiu DK,Peng YS.Immunohistochemical study of hepatic oval cells in human chronic vital hepatitis.World J Gastroenterol.2001;7(2):238-42
[87]Domingu ez-malagon H,Gaytan-Graham S.Hepatocellular carcinoma:an update.Ultrastruct Pathol.2001;25(6):497-516
[88]Fang CH,Zhang W,Zhu XY,et al.The expression of c-kit and proliferating cell nucleur antigen in oval cells of rats with hepatocellulaet carcinama.Hepatobiliary Pancreat Dis Int.2003;2(4):537-44
[89]Lowes KN,Brennan BA,Yeoh Gc et al.Oval cell numbers in human chronic liver diseases are directly related to disease severity.Am J Pathol,1999,154:537-541?
[90]Thorgeirsson SS,Factor VM,Synderwine EG.Transgenic mouse moels in carsinogenesis research and testing.Toxicol letl 2000,112-113:553-555
[91]Libbrecht L,Meerman L,Kuipers F,er al.Liver pathology and hepatocvarcinogenesis in a long term mouse model of evythropropoietic protoporphyria.[J]Pathol 2003,199:191-200
[92]Hsia CC,Evarts RP,Nakatsukasa H,et al.Occurrence of oval-type cells in hepatitis B virus-assaciated human hepatocarcinogenesis.Hepatology 1997,16:1327-1333
[93]Tania Roskams, Shi QiYang.Aymen Koteish, et al.Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease.American Journal of Pathololy.2003 .163(4): 1301-1311
[94]Michalopoulos G.Liver regeneration molecular mechanism of growth of growth ontrol.Faseb J, 4.1990, 176-187
[95]Okano J, Shiota G, Matsumoto K, et al.Hepatocy growth factor exerts a proliferative effect on oval cells through the PI3K/AKT signaling pathway.Biochem biophys res commun.2003 19; 309(2): 298-304
[96]Sautin YY, Jorgensen M, Petersen BE, et al.Hepatic oval cell expression of endothelial differentiation gene receptors for lysophosphetidic acid in mouse chronic liver injury.[J]Hematother stem cell Res, 2002.11(4): 643-9
[97]Libbrecht L, Roskams T.Hepatic progenitor cells in human liver diseases.Semin cell dev boil.2002; 13(6): 389-96
[98]Hatch HM, Zheng D, Jorgensen ML, et al.SDF-lalpha/CXCR4: a mechanism for hepatic oval cell activation and bone marrow stem cell recruitment to the injuried liver of rats.Cloning stem cells.2002; 4(4): 339-51
[99]Chen JZ, Hang H, Xiang J, et al.A selective tropism of transfused oval cells for liver.World J Gastroenterol.2003; 9(3): 544-6
[100]Oh SH, Hatch HM, Petersen BE.Hepatic oval stem cell in liver regeneration.Semin cell dev boil.2002; 13(6): 405-9
[101]He ZP, Tan WQ, Tang YF, et al.Differentiation of putative hepatic stem cell derived from adult rats into mature hepatocytes in the presence of epidermal growth factor and hepatocyte growth factor.Differentiation.2003,71(45): 287-90
[102]Petersen BE, Grossbard B, Hatch H, et al.Mouse A6-positive hepatic oval cells also express several hematopoietic stem cell markers.Hepatology.2003, 37(3): 625-40
[103]Kumar KS, Lefkowitch J.Russo MW, et al.Successful sequential liver and stem cell transplantation for hepatic failture due to primary Alamyloidosis.Gastroenterology, 2002, 122: 2026-2031
[104]Tordoff GM,Novin D.Celiac vagotomy attenuates the ingestive responses to epinephrine and hypertonic saline but not insulin,2-deoxy-D-glucose,or polyethylene glycol[J].Physiol Behav,1982,29(4):605-613.
[105]Akiyoshi H,Gonda T,Terada T.A comparative histochemical and immunohisto-chemical study of aminergic,cholinergic and peptidergic innervation in rat,hamster,guinea pig,dog and human livers[J].Liver,1998,18(5):352-359.
[106]Fukuda Y,Imoto M,Koyama Y,et al.Demonstration of noradrena-line-immunoreactive nerve fibres in the liver[J].J Int Med Res,1996,24(6):466-472.
[107]HuangQH,Takaki A,Arimura A.Central noradrenergic systemrnodulats plasma interleukin-6 production by peripheral interleukin-1[J].Am J Physiol.1997,273(2 Pt2):R731-738.
[108]Haeusler G.Early pre-post junctional effects of 6-hydroxydopamine[J].J Phar macol Exp Ther,1971,178(1):49-62.
[109]Matsuda Y,Matsumoto K,Yamada A,Ichida T,Asakura H,Komoriya-Y,Nishiyama E,Nakamura T.Preventive and Therapeutic Effects in Rats of Hepatocyte Growth Factor Infusion on Liver Fibrosis/ Cirrhosis.Hepatology 1997;26:81-89
[110]中华医学会传染病与寄生虫病学分会,肝病学分会联合修订.病毒性肝炎防治方案.中华肝脏病杂志,2000,8:324-9
[111]Alison MR,Poulsom R,Forbes SJ.Update on hepatic stem cells[J].Liver,2001,21(6):367-373.
[112]金树根,王灵台,任家淮,等.二甲基亚硝胺致大鼠肝纤维化的造模研究[J].中西医结合肝病杂志,1994,4(1):28-30.
[113]George J,Chandrakasan G.Lactate dehydrogenase isoenzymes in dimethylnitro-samine induced hepatic fibrosis in rats[J].J clin Biochem Nutr,1997,22:51-52.
[114]Shiba M,Shimizu I,Yaauda M,et al.Expression of type I and type IV collagens during the courseof dimethylnitrosamine induced hepatic fibrosis in rats[J].Liver,1998,18:196-200.
[115]Tsursumi M,Urashima S,Nakase Ket al.Change in laminin content in livers of patients with alcoholic liver disease.Liver,1995;15(6):324-31.
[116]Dunsford HA,Sell S.Production of monoclonal antibodies to preneoplastic liver cell populations induced by chemical carcinogens in rats and to transplantable Morris hepatomas[J].Cancer Res,1989,49(17):4887-4893.
[117]Silva GV,Litovsky S,Assad JA.et al.Mesenchymal stem cells differentiate into an endothelial phenotype,enhance vascular density,and improve heart function in a canine chronic ischemia model.Circulation 2005:111(2):150-156.
[118]Grompe M.Adult versus embryonic stem cells:It's still a tie.Mol Ther,2002.6:303-305.
[119]Jude A.Oben et al.Sympathetic Nervous System Inhibition Increases Hepatic Progenitors and Reduces Liver Injury.HEPATOLOGY,2003,38(3):664-673
[120]Jude A.Oben and Anna Mae Diehl.Sympathetic Nervous System Regulation of Liver Repair.THE ANATOMICAL RECORD PART A 280A:874-883
[121]KimH,Booth CJ,PinusAB,et al.Induced hepatic fibrosis in rats:hepatic steatosis,macromolecule content,perfusion parameters,and their correlations—preliminary MR imaging in rats[J].Radiology,2008,247(3):696-705.
[122]Flisiak R,Maxwell P,Prokopowicz D,etal.Plasma tissue inhibitor of metallo-proteinases-1and transforming growth factor beta 1—possible non-invasive biomarkers of hepatic fibrosis in patients with chronic B and C hepatitis[J].Hepato-gastroenterology,2002,49(47):1369-1372.
[123]Chandru H,Sharada AC,Manjunath S.Expression of matrix metalloproteinase (MMP-2)and extracellular matrix metalloproteinases inducer(EMMPRIN)in benign and advanced breast cancer tissue samples[J].Biomed Khim,2007.53(4):461-467.
[124]KornekM,Raskopf E,Guetgemann I,et al.Combination of systemic thioacetamide(TAA)injections and ethanol feeding accelerates hepatic fibrosis in C3H/He mice and is associated with intrahepatic up regulation of MMP-2,VEGF and ICAM-1[J].J Hepatol,2006,45(3):370-376.
[125]吴其恺,杨大国,陶艳艳,等.正肝化瘀方对肝纤维化大鼠肝组织MMPs和TIMPs蛋白表达的影响[J].中西医结合肝病杂志,2008,18(1):35-37.
[126]Goto T,Mikami KI,Miura K,et al.Department of Gastroenterology, Mechanical stretch induce smatrixmetalloproteinasel production in human hepatic stellate cells[J].Pathophysiology,2004,1 l(3):153-158.
[127]Abe S,Amagasaki Y,Lyori S,et al,Significance of tubuloint-erstitial lesions in biopsy specimens of glomerulonephritic ptients[J].Am J Nephrol Hypertents,1989,9:30
[128]Ryseck RP,Macdonld-Bravo H,Mattei MG,et al.Structure,mapping,and expression of fisp-12,a growth factor-inducible gene encoding a screted cysteine-rich protein[J].Cell GrowthDiffer,1991,2:225-233.
[129]Weng HL,Ciuclan L,Liu Y,Hamzavi J,Godoy P,Gaitantzi H,Kanzler S,Heuchel R,Ueberham U,Gebhardt R,Breitkopf K,Dooley S.Profibrogenic transforming growth factor-beta/activin receptor-like kinase 5 signaling via connective tissue growth factor expression in hepatocytes.Hepatology 2007;46:1257-1270
[130]GressnerAM,Weiskirchen R,BreitkoptK,et al Roles ofrGF-beta in hepatic fibrosis[J].FrontBiosc,i 2002,7:d793-807.
[131]Blom IE,Goldschmeding R,Leask A.Gene regulation of connective tissue growth factor:new targets for antifibrotic therapy?[J].Matrix Biol,2002,21(6):473.
[132]牟善初,赵海潞.老年肾问质纤维化时转化生长因子β_1的免疫电镜观察.解放军医学杂志,2000,25(6):434
[133]Dooley S,Delvoux B,Streckert Met al.Transforming growth factor beta signal transduction in hepatic stellate cells via Smad2/3 phosphorylation,a pathway that isabrogated duringin vitroprogression to myofibroblasts.TGFbeta signal transduction during transdifferentiation of hepatic stellate cells.FEBS Lett,2001,502(1-2):4
[134]Yamatani T,Kobayashi H,Tezuka Ket al.Establishment of the enzyme linked immunosorbent assay for connective tissue growth factor(CTGF)and its detection in the sera of biliary atresia.Biochem Biophys Res Commun,1998,251(3):748
[135]Paradis V,Dargere D,Bonvoust Fet al.Effectsand regulation of connective tissue growth factor on hepatic stellate cells.Lab Invest,2002.82(6):767
[136]Saegusa S,Isaji S,Kawarada Y.Changes in serum hyaluronic acid levels and expression of CD44 and CD44 mRNA in hepatic sinusoidal endothelial cells after major hepatectomy in cirrhotic rats[J].World J Surg,2002,26(6):694.
[137]赵丽娟,李红,杨世杰,等.黄芪注射液对D-半乳糖胺所致小鼠急性肝损伤的保护作用[J].吉林大学学报:医学版,2003.29(3):280-282
[138]Hansson EM,Lendahl U,Chapman G.Notch signaling in development and disease.Semin Cancer Biol,2004,14(5):320-328.
[139]Henrique D,HirsingerE,Adam J,et a.1 Maintenance of neuroepi thelial progenitor cells by Delta-Notch signaling in the embryonic chick retina[J].CurrBio,1 1997,7(9):661-670.
[140]Iwata M,Awaya N,Graf L,et al.Human marrow stromal cells activate monocytes to secrete osteopontin,which down regulates Notch 1 gene expression in CD34+cells.Blood,2004,103(12):4496-4502.
[141]Bicknell R,Harris AL.Novel angiogenic signaling pathways and vascular targets.Annu Rev Pharmacol Toxicol,2004,44:219-238.